Compare PXED & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | MDXG |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 530.2M |
| IPO Year | N/A | 2007 |
| Metric | PXED | MDXG |
|---|---|---|
| Price | $29.40 | $3.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $44.29 | $9.00 |
| AVG Volume (30 Days) | 79.5K | ★ 1.8M |
| Earning Date | 04-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | $13.02 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $23.52 | $3.03 |
| 52 Week High | $38.19 | $7.99 |
| Indicator | PXED | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 47.50 |
| Support Level | $28.60 | $3.11 |
| Resistance Level | $30.85 | $7.39 |
| Average True Range (ATR) | 1.40 | 0.16 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.88 | 79.43 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.